到 2030 年联合治疗药物的市场预测：按类型、剂型、应用、最终用户和地区进行全球分析

根据 Stratistics MRC 的数据，2023 年全球联合治疗药物市场规模为 1,972 亿美元，预计到 2030 年将达到 3,651 亿美元，预测期内年复合成长率为 9.2%。

联合治疗是同时或依序给药两种或多种药物或治疗剂以治疗特定疾病或病症的医学策略。联合治疗在癌症、感染疾病、心血管疾病和许多其他医学领域都有应用。药物组合可以最大限度地提高疗效，同时限制不良反应。

药物开发的技术进步

药物研发技术的发展极大地改善了联合治疗领域，在许多医学疾病的治疗中提供了许多优势。基因组学和分子谱分析等技术的发展使得根据患者独特的基因谱定製药物组合成为可能。这样可以根据患者和疾病的独特特征个体化治疗，最大限度地提高疗效，同时最大限度地减少副作用。这可能有助于预测期内的市场发展。

副作用增加

当同时服用多种药物时，副作用或不良反应的机会可能会增加。患者可能会遇到更强的药物交互作用和副作用，使治疗难以忍受。联合用药可能会导致累积毒性，即某些化学物质随着时间的推移在体内积累，从而导致器官损伤和其他不良反应。这是阻碍市场拓展的主要问题。

提高利益意识

联合治疗是使用两种或多种药物来治疗特定疾病或病症。它有很多好处，包括提高治疗效果和减少副作用。一个重要的优势是多种药物协同作用并针对许多疾病相关因素，通常会产生更好的结果。此外，组合多种药物可以减少所需的个别给药，减少副作用，并提高患者对治疗的依从性。这些都是影响Maquette成长的因素。

成本上升

各种药物的使用会显着增加整体治疗费用。这可能会对某些个人的取得造成障碍，特别是在资源有限的医疗保健系统中。尤其是在医疗保健社会化和公共支持的国家，联合用药的高昂成本给医疗保健系统带来了压力。由于成本效益和财政限制，政府常常必须就将哪些治疗纳入处方笺中做出艰难的选择。这是限制市场拓展的因素。

COVID-19 的影响：

当 COVID-19 中断时，联合治疗的临床试验正在进行中。疫情导致多项临床试验暂停或推迟，影响了未来的药物核准时间表和患者获得最先进治疗的机会。疫情暴露了全球医药供应链的弱点。药品生产和分销的中断导致一些地区某些联合治疗药物的短缺。

甘草酸二铵业务预计将成为预测期内最大的业务

甘草酸二铵业务预计将成为预测期内最大的业务。甘草酸二铵 (DAG) 是一种植物生长调节剂。 DAG 天然存在于甘草根中，在中药中用于治疗感冒和咳嗽。人们已经研究了 DAG 作为发炎药物的潜力，但它尚未能够与市场上已有的顶级非类固醇消炎剂区分开来。

预测期内年复合成长率最高的是心血管疾病领域

预计心血管疾病领域在预测期内年复合成长率最高。联合治疗是一种管理和治疗心臟和血管健康多个方面的方法。使用具有不同作用机制的多种药物。此策略经常用于治疗心血管疾病的危险因素，例如高血压、高胆固醇和血栓形成。他汀类药物和抗血小板药物等药物的使用是心血管疾病联合治疗的常见组成部分。

比最大的地区

预计北美在预测期内将占据最大的市场占有率。生技公司、学术机构和研究机构也透过在药物研发发现和研发方面的合作，为该产业的扩张做出贡献。由于大众对联合治疗益处的认识不断提高，癌症、糖尿病和心血管疾病等慢性病患病率上升，以及药物研发的进步等因素，对新药物联合治疗的需求不断增加。

复合年复合成长率最高的地区：

预计亚太地区在预测期内年复合成长率最高。全部区域癌症、糖尿病和心血管疾病等慢性疾病的负担正在增加。药物组合在复杂疾病的治疗中变得越来越重要。该地区许多国家正在增加医学研究和基础设施的支出，这支持了联合疗法的创建和广泛普及。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

• 公司简介
  • 其他市场参与者的综合分析（最多 3 家公司）
  • 主要企业SWOT分析（最多3家企业）
• 区域分割
  • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
• 竞争基准化分析
  • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

• 概述
• 利害关係人
• 调查范围
• 调查方法
  • 资料探勘
  • 资料分析
  • 资料检验
  • 研究途径
• 调查来源
  • 主要调查来源
  • 二次调查来源
  • 先决条件

第3章市场趋势分析

• 促进因素
• 抑制因素
• 机会
• 威胁
• 应用分析
• 最终用户分析
• 新兴市场
• 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

• 供应商的议价能力
• 买方议价能力
• 替代品的威胁
• 新进入者的威胁
• 竞争公司之间的敌对关係

第5章全球联合治疗药物市场：依类型

• 干扰素药物和核苷类药物
• 标靶治疗药物
• 甘草酸二铵
• 其他类型

第6章全球联合治疗药物市场：按剂型

• 液体
• 固体的

第7章全球联合治疗药物市场：依应用分类

• 癌症
• 循环系统疾病
• 免疫疾病
• 其他用途

第8章全球联合治疗药物市场：依最终使用者分类

• 诊所
• 医院
• 其他最终用户

第9章全球联合治疗药物市场：按地区

• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙
  • 其他欧洲国家
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 纽西兰
  • 韩国
  • 其他亚太地区
• 南美洲
  • 阿根廷
  • 巴西
  • 智利
  • 南美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 卡达
  • 南非
  • 其他中东和非洲

第10章进展

• 合约、伙伴关係、协作和合资企业
• 收购和合併
• 新产品发布
• 业务扩展
• 其他关键策略

第11章公司简介

• WebMD LLC
• CSL Ltd
• Grifols SA
• Baxalta Incorporated
• Octapharma AG
• Kedrion SpA
• China Biologic Products
• Roche
• Pfizer
• Eli Lilly
• Johnson & Johnson
• Novartis
• Gilead Sciences
• AstraZeneca
• Merck & Co.
• Sanofi

According to Stratistics MRC, the Global Combination Therapy Drug Market is accounted for $197.2 billion in 2023 and is expected to reach $365.1 billion by 2030 growing at a CAGR of 9.2% during the forecast period. Combination therapy is a medical treatment strategy that entails the simultaneous or sequential administration of two or more medications or therapeutic agents to treat a particular illness or medical condition. Combination treatment has applications in cancer, infectious disorders, cardiovascular issues, and more areas of medicine. The combination of the medications may maximize effectiveness while reducing negative effects.

Market Dynamics:

Driver:

Technological advancements in drug development

The field of combination therapy has been greatly improved by technological developments in drug creation, giving a number of benefits in the treatment of many medical diseases. Technological developments like genomics and molecular profiling enable combination medicines to be tailored based on a patient's particular genetic profile. This allows for individualized treatment that maximizes efficacy while minimizing negative effects based on the unique qualities of the patient and the ailment. Over the projection period, this is probably going to help the market develop.

Restraint:

Increased side effects

The chance of side effects or negative reactions may rise while taking various medications together. Patients encounter stronger medication interactions or adverse effects, which might make the therapy less tolerable. Combining medications can result in cumulative toxicity, a condition in which the body gradually builds up more of a particular chemical, perhaps resulting in organ damage or other negative effects. This is the main issue impeding market expansion.

Opportunity:

Growing awareness about the benefits

Combination treatment is the use of two or more medications to treat a specific illness or medical condition. It has a number of benefits chief among them improved therapeutic effectiveness and fewer adverse effects. Multiple medications acting synergistically to target many disease-related factors are one important advantage, which frequently results in better results. Additionally, combining medications can reduce the necessary individual dosages, decreasing adverse effects and improving patient compliance with therapy. These are the factors influencing the growth of the maket.

Threat:

Higher costs

The cost of therapy as a whole can be greatly raised by the usage of various medications. For certain individuals, especially in healthcare systems with constrained resources, this might be a barrier to access. Particularly in nations with socialized or publicly supported healthcare, the high expense of combination medicines can put a burden on healthcare systems. Governments frequently have to make difficult choices about which treatments to include in their formularies due to cost-effectiveness and financial restrictions. This is the element limiting market expansion.

COVID-19 Impact:

Clinical studies for combination treatments were being conducted when COVID-19 disturbed them. The pandemic caused several trials to be either suspended or postponed, which had an impact on the schedule for prospective medication approvals and patient access to cutting-edge therapies. The epidemic revealed weaknesses in the world's medicine supply networks. There were shortages of several combination treatment medications in some areas due to disruptions in pharmaceutical manufacture and distribution.

The diammonium glycyrrhizinate segment is expected to be the largest during the forecast period

The diammonium glycyrrhizinate segment is expected to be the largest during the forecast period. Diammonium glycyrrhizinate (DAG) is a plant growth regulator. It is naturally present in licorice plant roots, which are used in traditional Chinese medicine to cure colds and coughs. DAG has been investigated for its potential as an anti-inflammatory medication, however it failed to demonstrate any appreciable distinction from the top non-steroidal anti-inflammatory medications already on the market.

The cardiovascular disease segment is expected to have the highest CAGR during the forecast period

The cardiovascular disease segment is expected to have the highest CAGR during the forecast period. Combination treatment is a method for managing and treating several aspects of heart and vascular health. It uses a number of medications with varied modes of action. This strategy is frequently used to treat risk factors for cardiovascular disorders, such as high blood pressure, high cholesterol, and blood clot formation. Utilizing drugs like statins and antiplatelet agents is a common component of combination therapy for cardiovascular disease.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Through their joint efforts in medication discovery and development, biotechnology companies, academic institutions, and research organizations also contribute to the expansion of this industry. The desire for novel combination medicines is being driven by causes such as rising public knowledge of the advantages of combination therapy, rising rates of chronic illnesses including cancer, diabetes, and cardiovascular problems, and improvements in pharmaceutical research and development.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The burden of chronic illnesses including cancer, diabetes, and cardiovascular conditions was growing throughout the area. Drug combinations were becoming increasingly important for treating complicated medical disorders. Many nations in the area were expanding their expenditures on medical research and infrastructure, which aided in the creation and uptake of combination treatment medications.

Key players in the market

Some of the key players in Combination Therapy Drug market include: WebMD LLC, CSL Ltd, Grifols S.A, Baxalta Incorporated, Octapharma AG, Kedrion S.p.A, China Biologic Products, Roche, Pfizer, Eli Lilly, Johnson & Johnson, Novartis, Gilead Sciences, AstraZeneca, Merck & Co. and Sanofi.

Key Developments:

In July 2023, Flagship Pioneering, Inc. and Pfizer Inc. announced the companies have partnered to create a new pipeline of innovative medicines. Under the terms of the novel agreement, Flagship and Pfizer will each invest $50M upfront to explore opportunities to develop 10 single-asset programs.

In November 2022, Arcturus Therapeutics Holdings Inc. announced a strategic collaboration with CSL Seqirus. CSL Seqirus' vaccine portfolio includes the world's second largest influenza vaccine franchise. CSL Seqirus is part of CSL Limited

In September 2022, WebMD Health Services announced a new partnership with Fern Health, a leading digital platform giving employees and health plan members the guidance and tools they need to address the underlying causes of persistent pain.

Types Covered:

• Interferon and Nucleoside Drugs
• Targeted Therapies Drugs
• Diammonium Glycyrrhizinate
• Other Types

Drug Forms Covered:

• Liquid
• Solid

Applications Covered:

• Cancer
• Cardiovascular Disease
• Immune Disease
• Other Applications

End Users Covered:

• Clinic
• Hospital
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Combination Therapy Drug Market, By Type

• 5.1 Introduction
• 5.2 Interferon and Nucleoside Drugs
• 5.3 Targeted Therapies Drugs
• 5.4 Diammonium Glycyrrhizinate
• 5.5 Other Types

6 Global Combination Therapy Drug Market, By Drug Form

• 6.1 Introduction
• 6.2 Liquid
• 6.3 Solid

7 Global Combination Therapy Drug Market, By Application

• 7.1 Introduction
• 7.2 Cancer
• 7.3 Cardiovascular Disease
• 7.4 Immune Disease
• 7.5 Other Applications

8 Global Combination Therapy Drug Market, By End User

• 8.1 Introduction
• 8.2 Clinic
• 8.3 Hospital
• 8.4 Other End Users

9 Global Combination Therapy Drug Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 WebMD LLC
• 11.2 CSL Ltd
• 11.3 Grifols S.A
• 11.4 Baxalta Incorporated
• 11.5 Octapharma AG
• 11.6 Kedrion S.p.A
• 11.7 China Biologic Products
• 11.8 Roche
• 11.9 Pfizer
• 11.10 Eli Lilly
• 11.11 Johnson & Johnson
• 11.12 Novartis
• 11.13 Gilead Sciences
• 11.14 AstraZeneca
• 11.15 Merck & Co.
• 11.16 Sanofi

List of Tables

• Table 1 Global Combination Therapy Drug Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Combination Therapy Drug Market Outlook, By Type (2021-2030) ($MN)
• Table 3 Global Combination Therapy Drug Market Outlook, By Interferon and Nucleoside Drugs (2021-2030) ($MN)
• Table 4 Global Combination Therapy Drug Market Outlook, By Targeted Therapies Drugs (2021-2030) ($MN)
• Table 5 Global Combination Therapy Drug Market Outlook, By Diammonium Glycyrrhizinate (2021-2030) ($MN)
• Table 6 Global Combination Therapy Drug Market Outlook, By Other Types (2021-2030) ($MN)
• Table 7 Global Combination Therapy Drug Market Outlook, By Drug Form (2021-2030) ($MN)
• Table 8 Global Combination Therapy Drug Market Outlook, By Liquid (2021-2030) ($MN)
• Table 9 Global Combination Therapy Drug Market Outlook, By Solid (2021-2030) ($MN)
• Table 10 Global Combination Therapy Drug Market Outlook, By Application (2021-2030) ($MN)
• Table 11 Global Combination Therapy Drug Market Outlook, By Cancer (2021-2030) ($MN)
• Table 12 Global Combination Therapy Drug Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
• Table 11 Global Combination Therapy Drug Market Outlook, By Immune Disease (2021-2030) ($MN)
• Table 14 Global Combination Therapy Drug Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 15 Global Combination Therapy Drug Market Outlook, By End User (2021-2030) ($MN)
• Table 16 Global Combination Therapy Drug Market Outlook, By Clinic (2021-2030) ($MN)
• Table 17 Global Combination Therapy Drug Market Outlook, By Hospital (2021-2030) ($MN)
• Table 18 Global Combination Therapy Drug Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 19 North America Combination Therapy Drug Market Outlook, By Country (2021-2030) ($MN)
• Table 20 North America Combination Therapy Drug Market Outlook, By Type (2021-2030) ($MN)
• Table 21 North America Combination Therapy Drug Market Outlook, By Interferon and Nucleoside Drugs (2021-2030) ($MN)
• Table 22 North America Combination Therapy Drug Market Outlook, By Targeted Therapies Drugs (2021-2030) ($MN)
• Table 23 North America Combination Therapy Drug Market Outlook, By Diammonium Glycyrrhizinate (2021-2030) ($MN)
• Table 24 North America Combination Therapy Drug Market Outlook, By Other Types (2021-2030) ($MN)
• Table 25 North America Combination Therapy Drug Market Outlook, By Drug Form (2021-2030) ($MN)
• Table 26 North America Combination Therapy Drug Market Outlook, By Liquid (2021-2030) ($MN)
• Table 27 North America Combination Therapy Drug Market Outlook, By Solid (2021-2030) ($MN)
• Table 28 North America Combination Therapy Drug Market Outlook, By Application (2021-2030) ($MN)
• Table 29 North America Combination Therapy Drug Market Outlook, By Cancer (2021-2030) ($MN)
• Table 30 North America Combination Therapy Drug Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
• Table 31 North America Combination Therapy Drug Market Outlook, By Immune Disease (2021-2030) ($MN)
• Table 32 North America Combination Therapy Drug Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 33 North America Combination Therapy Drug Market Outlook, By End User (2021-2030) ($MN)
• Table 34 North America Combination Therapy Drug Market Outlook, By Clinic (2021-2030) ($MN)
• Table 35 North America Combination Therapy Drug Market Outlook, By Hospital (2021-2030) ($MN)
• Table 36 North America Combination Therapy Drug Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 37 Europe Combination Therapy Drug Market Outlook, By Country (2021-2030) ($MN)
• Table 38 Europe Combination Therapy Drug Market Outlook, By Type (2021-2030) ($MN)
• Table 39 Europe Combination Therapy Drug Market Outlook, By Interferon and Nucleoside Drugs (2021-2030) ($MN)
• Table 40 Europe Combination Therapy Drug Market Outlook, By Targeted Therapies Drugs (2021-2030) ($MN)
• Table 41 Europe Combination Therapy Drug Market Outlook, By Diammonium Glycyrrhizinate (2021-2030) ($MN)
• Table 42 Europe Combination Therapy Drug Market Outlook, By Other Types (2021-2030) ($MN)
• Table 43 Europe Combination Therapy Drug Market Outlook, By Drug Form (2021-2030) ($MN)
• Table 44 Europe Combination Therapy Drug Market Outlook, By Liquid (2021-2030) ($MN)
• Table 45 Europe Combination Therapy Drug Market Outlook, By Solid (2021-2030) ($MN)
• Table 46 Europe Combination Therapy Drug Market Outlook, By Application (2021-2030) ($MN)
• Table 47 Europe Combination Therapy Drug Market Outlook, By Cancer (2021-2030) ($MN)
• Table 48 Europe Combination Therapy Drug Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
• Table 49 Europe Combination Therapy Drug Market Outlook, By Immune Disease (2021-2030) ($MN)
• Table 50 Europe Combination Therapy Drug Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 51 Europe Combination Therapy Drug Market Outlook, By End User (2021-2030) ($MN)
• Table 52 Europe Combination Therapy Drug Market Outlook, By Clinic (2021-2030) ($MN)
• Table 53 Europe Combination Therapy Drug Market Outlook, By Hospital (2021-2030) ($MN)
• Table 54 Europe Combination Therapy Drug Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 55 Asia Pacific Combination Therapy Drug Market Outlook, By Country (2021-2030) ($MN)
• Table 56 Asia Pacific Combination Therapy Drug Market Outlook, By Type (2021-2030) ($MN)
• Table 57 Asia Pacific Combination Therapy Drug Market Outlook, By Interferon and Nucleoside Drugs (2021-2030) ($MN)
• Table 58 Asia Pacific Combination Therapy Drug Market Outlook, By Targeted Therapies Drugs (2021-2030) ($MN)
• Table 59 Asia Pacific Combination Therapy Drug Market Outlook, By Diammonium Glycyrrhizinate (2021-2030) ($MN)
• Table 60 Asia Pacific Combination Therapy Drug Market Outlook, By Other Types (2021-2030) ($MN)
• Table 61 Asia Pacific Combination Therapy Drug Market Outlook, By Drug Form (2021-2030) ($MN)
• Table 62 Asia Pacific Combination Therapy Drug Market Outlook, By Liquid (2021-2030) ($MN)
• Table 63 Asia Pacific Combination Therapy Drug Market Outlook, By Solid (2021-2030) ($MN)
• Table 64 Asia Pacific Combination Therapy Drug Market Outlook, By Application (2021-2030) ($MN)
• Table 65 Asia Pacific Combination Therapy Drug Market Outlook, By Cancer (2021-2030) ($MN)
• Table 66 Asia Pacific Combination Therapy Drug Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
• Table 67 Asia Pacific Combination Therapy Drug Market Outlook, By Immune Disease (2021-2030) ($MN)
• Table 68 Asia Pacific Combination Therapy Drug Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 69 Asia Pacific Combination Therapy Drug Market Outlook, By End User (2021-2030) ($MN)
• Table 70 Asia Pacific Combination Therapy Drug Market Outlook, By Clinic (2021-2030) ($MN)
• Table 71 Asia Pacific Combination Therapy Drug Market Outlook, By Hospital (2021-2030) ($MN)
• Table 72 Asia Pacific Combination Therapy Drug Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 73 South America Combination Therapy Drug Market Outlook, By Country (2021-2030) ($MN)
• Table 74 South America Combination Therapy Drug Market Outlook, By Type (2021-2030) ($MN)
• Table 75 South America Combination Therapy Drug Market Outlook, By Interferon and Nucleoside Drugs (2021-2030) ($MN)
• Table 76 South America Combination Therapy Drug Market Outlook, By Targeted Therapies Drugs (2021-2030) ($MN)
• Table 77 South America Combination Therapy Drug Market Outlook, By Diammonium Glycyrrhizinate (2021-2030) ($MN)
• Table 78 South America Combination Therapy Drug Market Outlook, By Other Types (2021-2030) ($MN)
• Table 79 South America Combination Therapy Drug Market Outlook, By Drug Form (2021-2030) ($MN)
• Table 80 South America Combination Therapy Drug Market Outlook, By Liquid (2021-2030) ($MN)
• Table 81 South America Combination Therapy Drug Market Outlook, By Solid (2021-2030) ($MN)
• Table 82 South America Combination Therapy Drug Market Outlook, By Application (2021-2030) ($MN)
• Table 83 South America Combination Therapy Drug Market Outlook, By Cancer (2021-2030) ($MN)
• Table 84 South America Combination Therapy Drug Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
• Table 85 South America Combination Therapy Drug Market Outlook, By Immune Disease (2021-2030) ($MN)
• Table 86 South America Combination Therapy Drug Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 87 South America Combination Therapy Drug Market Outlook, By End User (2021-2030) ($MN)
• Table 88 South America Combination Therapy Drug Market Outlook, By Clinic (2021-2030) ($MN)
• Table 89 South America Combination Therapy Drug Market Outlook, By Hospital (2021-2030) ($MN)
• Table 90 South America Combination Therapy Drug Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 91 Middle East & Africa Combination Therapy Drug Market Outlook, By Country (2021-2030) ($MN)
• Table 92 Middle East & Africa Combination Therapy Drug Market Outlook, By Type (2021-2030) ($MN)
• Table 93 Middle East & Africa Combination Therapy Drug Market Outlook, By Interferon and Nucleoside Drugs (2021-2030) ($MN)
• Table 94 Middle East & Africa Combination Therapy Drug Market Outlook, By Targeted Therapies Drugs (2021-2030) ($MN)
• Table 95 Middle East & Africa Combination Therapy Drug Market Outlook, By Diammonium Glycyrrhizinate (2021-2030) ($MN)
• Table 96 Middle East & Africa Combination Therapy Drug Market Outlook, By Other Types (2021-2030) ($MN)
• Table 97 Middle East & Africa Combination Therapy Drug Market Outlook, By Drug Form (2021-2030) ($MN)
• Table 98 Middle East & Africa Combination Therapy Drug Market Outlook, By Liquid (2021-2030) ($MN)
• Table 99 Middle East & Africa Combination Therapy Drug Market Outlook, By Solid (2021-2030) ($MN)
• Table 100 Middle East & Africa Combination Therapy Drug Market Outlook, By Application (2021-2030) ($MN)
• Table 101 Middle East & Africa Combination Therapy Drug Market Outlook, By Cancer (2021-2030) ($MN)
• Table 102 Middle East & Africa Combination Therapy Drug Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
• Table 103 Middle East & Africa Combination Therapy Drug Market Outlook, By Immune Disease (2021-2030) ($MN)
• Table 104 Middle East & Africa Combination Therapy Drug Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 105 Middle East & Africa Combination Therapy Drug Market Outlook, By End User (2021-2030) ($MN)
• Table 106 Middle East & Africa Combination Therapy Drug Market Outlook, By Clinic (2021-2030) ($MN)
• Table 107 Middle East & Africa Combination Therapy Drug Market Outlook, By Hospital (2021-2030) ($MN)
• Table 108 Middle East & Africa Combination Therapy Drug Market Outlook, By Other End Users (2021-2030) ($MN)